ESTRO Multidisciplinary Management of Breast Cancer 2017

TAM 5 years vs TAM 10 years

Thrombo-embolic disease RR: 1.87 ( p:0.01)

Endometrial cancer RR: 1.74 ( p: 0.0002) Incidence of endometrial cancer 3.1% in the tamoxifen arm vs. 1.6% (placebo). Endometrial cancer–related mortality was 0.4% in the tamoxifen arm vs. 0.2% in the placebo arm.

When compared to no TAM, the RR of 10 year TAM is between 4 and 5

Davies et al, Lancet 2013